In recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; a number of players have developed proprietary technologies for direct and indirect RNA targeting, to treat a wide range of clinical conditions
Roots Analysis is pleased to announce the publication of its recent study, titled, “RNA Targeting Small Molecules Therapeutics Market”
The report features an extensive study of the current market landscape and future potential of the players engaged in the discovery and development of RNA targeting small molecules therapeutics. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:
- An in-depth review of the market landscape of players that are engaged in the discovery and development of RNA targeting small molecules therapeutics being evaluated at both preclinical and clinical stages of development. It also includes a detailed landscape of developers active in this domain.
- An insightful analysis of the company competitiveness and investment landscape comparing the key players engaged in the domain of RNA targeting small molecules. Further, it includes start-ups and investment activity across different players.
- An analysis of the partnerships that have been inked by stakeholders in this area, during the period between 2017 and 2021.
- An in-depth analysis of investments made, during the period between 2015 and 2021, in companies that are engaged in the development of RNA targeting small molecules therapeutics.
- Elaborate profiles of key players engaged in the development of RNA targeting small molecules therapeutics.
- A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
- Type of Target Disease Indication
- Aniridia
- Breast Cancer
- Castrate-resistant Prostate Cancer
- Colorectal Cancer
- Cystic Fibrosis
- Crohn’s Disease
- Duchenne Muscular Dystrophy
- Dravet Syndrome
- HIV Infections
- Impaired Renal Function
- NSCLC
- Rheumatoid Arthritis
- Spinal Muscular Atrophy
- Ulcerative Colitis
- Type of Therapeutic Area
- Autoimmune Disorders
- Genetic Disorders
- Inflammatory Disorders
- Infectious Disorders
- Kidney Disorders
- Neurological Disorders
- Oncological Disorders
- Ophthalmic Disorders
- Rare Disorders
- Respiratory Disorders
- Type of Target Molecule
- CDKL5
- Cap Binding Complex
- Dystrophin Protein
- Estrogen Receptor Alpha
- G542X
- MNK1 / MNK2
- PAX6 Gene
- SMN2
- Type of Approach
- Indirect RNA Targeting- Epitranscriptomics
- mRNA Translation Modulation
- RNA Splicing Modification
- Route of Administration
- Oral
- Subcutaneous
- Key Geographical Regions
- North America
- Europe
Transcripts of interviews held with the following senior level representatives of stakeholder companies
- Clara Assouline (Business Development, Anima Biotech)
- Dominique Cheneval (Co-Founder and Chief Executive Officer, Novation Pharmaceuticals)
Key companies covered in the report
- Abivax
- AC Immune
- Arrakis Therapeutics
- eFFECTOR Therapeutics
- ELOXX Pharmaceuticals
- PTC Therapeutics
- H3 Biomedicine
- Ribometrix
- Skyhawk Therapeutics
- STORM Therapeutics
For more information, please click on the following link
https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html
Other Recent Offerings
- RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
- DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
- HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
